Alumis (ALMS) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alumis (ALMS) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 57.3% versus a gain of 16.3%. Alumis is the larger company by market cap ($902.2 million vs $900.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | MLTX |
|---|---|---|
| Share price | $6.97 | $10.58 |
| Market cap | $902.16M | $900.43M |
| 1-day change | +2.95% | -1.76% |
| YTD return | -28.59% | -19.73% |
| 1-year return | +57.34% | +16.26% |
| 5-year return | — | +6.65% |
| EPS (TTM) | $-3.86 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $23.29 |
| 52-week low | $4.28 | $8.80 |
| Distance from 52-week high | -77.77% | -54.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +360.98% | +169.75% |
| Average volume | 2.43M | 1.47M |
| Shares outstanding | 129.44M | 85.11M |
| Employees | 237 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed MLTX by 41.1 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
ALMS vs MLTX FAQ
Which is bigger, Alumis or MoonLake Immunotherapeutics?
Alumis (ALMS) is larger, with a market capitalization of $902.16M compared with $900.43M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, ALMS or MLTX?
ALMS returned +57.34% over the past 12 months, compared with +16.26% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.